These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

657 related articles for article (PubMed ID: 25661187)

  • 1. Cost-effective treatment modalities for reducing morbidity associated with chronic kidney disease.
    Ferguson TW; Tangri N; Rigatto C; Komenda P
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):243-52. PubMed ID: 25661187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?
    Kent S; Schlackow I; Lozano-Kühne J; Reith C; Emberson J; Haynes R; Gray A; Cass A; Baigent C; Landray MJ; Herrington W; Mihaylova B;
    BMC Nephrol; 2015 Apr; 16():65. PubMed ID: 25924679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Healthcare costs in chronic kidney disease and renal replacement therapy: a population-based cohort study in Sweden.
    Eriksson JK; Neovius M; Jacobson SH; Elinder CG; Hylander B
    BMJ Open; 2016 Oct; 6(10):e012062. PubMed ID: 27855091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The right patient, the right treatment, the right access and the right time.
    Link DK; Saxena R
    Adv Chronic Kidney Dis; 2014 Jul; 21(4):360-4. PubMed ID: 24969388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost-effectiveness analysis of treatment for end-stage renal disease].
    Asgeirsdóttir TL; Asmundsdóttir G; Heimisdóttir M; Jónsson E; Pálsson R
    Laeknabladid; 2009 Nov; 95(11):747-53. PubMed ID: 19996463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health economic evaluations: the special case of end-stage renal disease treatment.
    Winkelmayer WC; Weinstein MC; Mittleman MA; Glynn RJ; Pliskin JS
    Med Decis Making; 2002; 22(5):417-30. PubMed ID: 12365484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of home telemonitoring in chronic kidney disease patients at different stages by a pragmatic randomized controlled trial (eNephro): rationale and study design.
    Thilly N; Chanliau J; Frimat L; Combe C; Merville P; Chauveau P; Bataille P; Azar R; Laplaud D; Noël C; Kessler M
    BMC Nephrol; 2017 Apr; 18(1):126. PubMed ID: 28381266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence, prevalence, treatment and cost of end-stage renal disease in Indonesia.
    Prodjosudjadi W
    Ethn Dis; 2006; 16(2 Suppl 2):S2-14-6. PubMed ID: 16774003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost effectiveness analysis of the treatment of end stage renal failure.
    Croxson BE; Ashton T
    N Z Med J; 1990 Apr; 103(888):171-4. PubMed ID: 2109846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost analysis of dialysis treatments for end-stage renal disease (ESRD).
    Goeree R; Manalich J; Grootendorst P; Beecroft ML; Churchill DN
    Clin Invest Med; 1995 Dec; 18(6):455-64. PubMed ID: 8714789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [When to start dialysis. The predialysis patient].
    Triolo G; Savoldi S
    G Ital Nefrol; 2008; 25 Suppl 41():S9-12, discussion S13-20. PubMed ID: 18473314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of dialysis therapies.
    Klarenbach S; Manns B
    Semin Nephrol; 2009 Sep; 29(5):524-32. PubMed ID: 19751898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing advanced chronic kidney disease: a primary care guide.
    Sakhuja A; Hyland J; Simon JF
    Cleve Clin J Med; 2014 May; 81(5):289-99. PubMed ID: 24789588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of economic impact between the modality of renal replacement therapy.
    Gouveia DSES; Bignelli AT; Hokazono SR; Danucalov I; Siemens TA; Meyer F; Santos LS; Martins ZCL; Mierzwa TC; Furquim R
    J Bras Nefrol; 2017; 39(2):162-171. PubMed ID: 28489179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of a pre-ESRD pay-for-performance programme in advanced chronic kidney disease patients.
    Hsieh HM; Lin MY; Chiu YW; Wu PH; Cheng LJ; Jian FS; Hsu CC; Hwang SJ
    Nephrol Dial Transplant; 2017 Jul; 32(7):1184-1194. PubMed ID: 28486670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic burden of chronic kidney disease in Korea using national sample cohort.
    Kim SH; Jo MW; Go DS; Ryu DR; Park J
    J Nephrol; 2017 Dec; 30(6):787-793. PubMed ID: 28303461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health benefits and costs of screening for colorectal cancer in people on dialysis or who have received a kidney transplant.
    Wong G; Li MW; Howard K; Hua DK; Chapman JR; Bourke M; Turner R; Tong A; Craig JC
    Nephrol Dial Transplant; 2013 Apr; 28(4):917-26. PubMed ID: 23182812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal transplantation vs hemodialysis: cost-effectiveness analysis.
    Perović S; Janković S
    Vojnosanit Pregl; 2009 Aug; 66(8):639-44. PubMed ID: 19780419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [REIN Report 2011--summary].
    Couchoud C; Lassalle M; Jacquelinet C
    Nephrol Ther; 2013 Sep; 9 Suppl 1():S3-6. PubMed ID: 24119584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost analysis of alternative treatments in end-stage renal disease.
    Karlberg I
    Transplant Proc; 1992 Feb; 24(1):335. PubMed ID: 1539301
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 33.